中度主动脉瓣狭窄对射血分数降低心衰患者预后的影响
本研究纳入262例中度主动脉瓣狭窄合并射血分数降低心衰(HFrEF)患者,按1:1匹配262例无主动脉瓣狭窄的HFrEF患者。中度主动脉瓣狭窄与全因死亡风险(HR 2.98)及心衰住院或死亡复合终点风险(HR 2.34)显著增加相关。随访期间行主动脉瓣置换(尤其经导管)与生存改善相关,支持开展随机试验评估早期经导管主动脉瓣置换。
要点
- 中度主动脉瓣狭窄使HFrEF患者全因死亡风险增加近3倍。
- 随访期主动脉瓣置换(尤其经导管)与生存改善相关。
- 结果支持随机试验评估HFrEF合并中度主动脉瓣狭窄的早期经导管主动脉瓣置换。
核心结论
- 在HFrEF患者中,中度主动脉瓣狭窄与死亡率显著增加独立相关。
- 随访期间行主动脉瓣置换(尤其经导管)与生存改善相关,支持开展随机试验评估早期经导管主动脉瓣置换。
研究设计与样本
- 研究纳入262例中度主动脉瓣狭窄(主动脉瓣面积>1.0且<1.5 cm2,峰值主动脉射流速度>2且<4 m/s,静息或多巴酚丁胺负荷超声心动图)合并HFrEF(LVEF<50%)患者。
- 按性别、年龄、估算肾小球滤过率、NYHA III-IV级、糖尿病、LVEF和体重指数1:1匹配262例无主动脉瓣狭窄(峰值主动脉射流速度<2 m/s)的HFrEF患者。
- 终点为全因死亡及死亡与心衰住院复合终点,平均随访2.9±2.2年。
主要发现
- 中度主动脉瓣狭窄组平均主动脉瓣面积为1.2±0.2 cm2,平均跨瓣压差为14.5±4.7 mm Hg。
- 中度主动脉瓣狭窄与死亡率增加相关(HR 2.98;95%CI 2.08-4.31;p<0.0001)。
- 中度主动脉瓣狭窄组44例患者在中位随访10.9±16个月时行主动脉瓣置换,与生存改善相关(HR 0.59;95%CI 0.35-0.98;p=0.04)。
- 外科主动脉瓣置换与生存改善无显著相关(p=0.92),经导管主动脉瓣置换与生存改善相关(HR 0.43;95%CI 0.18-1.00;p=0.05)。
关键数值与推荐
- 中度主动脉瓣狭窄定义:主动脉瓣面积>1.0且<1.5 cm2,峰值主动脉射流速度>2且<4 m/s(静息或负荷超声)。
- HFrEF定义:LVEF<50%。
- 无主动脉瓣狭窄定义:峰值主动脉射流速度<2 m/s。
临床怎么用
- HFrEF患者合并中度主动脉瓣狭窄时死亡风险显著增高,应加强风险评估与随访。
- 随访期间行主动脉瓣置换(尤其经导管)可能与生存改善相关,但需随机试验证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The study investigators previously reported that moderate aortic stenosis (AS) is associated with a poor prognosis in patients with heart failure (HF) with reduced left ventricular ejection fraction (LVEF) (HFrEF). However, the respective contribution of moderate AS versus HFrEF to the outcomes of these patients is unknown. OBJECTIVES: This study sought to determine the impact of moderate AS on outcomes in patients with HFrEF. METHODS: The study included 262 patients with moderate AS (aortic valve area >1.0 and <1.5 cm2; and peak aortic jet velocity >2 and <4 m/s, at rest or after dobutamine stress echocardiography) and HFrEF (LVEF <50%). These patients were matched 1:1 for sex, age, estimated glomerular filtration rate, New York Heart Association functional class III to IV, presence of diabetes, LVEF, and body mass index with patients with HFrEF but no AS (i.e., peak aortic jet velocity <2 m/s). The endpoints were all-cause mortality and the composite of death and HF hospitalization. RESULTS: A total of 262 patients with HFrEF and moderate AS were matched with 262 patients with HFrEF and no AS. Mean follow-up was 2.9 ± 2.2 years. In the moderate AS group, mean aortic valve area was 1.2 ± 0.2 cm2, and mean gradient was 14.5 ± 4.7 mm Hg. Moderate AS was associated with an increased risk of mortality (hazard ratio [HR]: 2.98; 95% confidence interval [CI]: 2.08 to 4.31; p < 0.0001) and of the composite of HF hospitalization and mortality (HR: 2.34; 95% CI: 1. 72 to 3.21; p < 0.0001). In the moderate AS group, aortic valve replacement (AVR) performed in 44 patients at a median follow-up time of 10.9 ± 16 months during follow-up was associated with improved survival (HR: 0.59; 95% CI: 0.35 to 0.98; p = 0.04). Notably, surgical AVR was not significantly associated with improved survival (p = 0.92), whereas transcatheter AVR was (HR: 0.43; 95% CI: 0.18 to 1.00; p = 0.05). CONCLUSIONS: In this series of patients with HFrEF, moderate AS was associated with a marked incremental risk of mortality. AVR, and especially transcatheter AVR during follow-up, was associated with improved survival in patients with HFrEF and moderate AS. These findings provide support to the realization of a randomized trial to assess the effect of early transcatheter AVR in patients with HFrEF and moderate AS.
引用
- Jean G, Van Mieghem NM, Gegenava T, et al. Moderate Aortic Stenosis in Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2021. PMID: 34082909. doi:10.1016/j.jacc.2021.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。